Understanding the multiple biological aspects leading to myeloma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. A Room for Long-Lived Plasma Cell Contribution in Immune Cytopenias?Cancers · 2025
   Review
2. Analysis of smoldering multiple myeloma according to the target of the monoclonal immunoglobulin of patients.HemaSphere · 2024
   Article
3. Perspectives on the Treatment of Multiple Myeloma.The oncologist · 2024
   Review
4. Multiple Myeloma Derived Extracellular Vesicle Uptake by Monocyte Cells Stimulates IL-6 and MMP-9 Secretion and Promotes Cancer Cell Migration and Proliferation.Cancers · 2024
   Article
5. Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses.Haematologica · 2024
   Article
6. Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report.World journal of clinical cases · 2022
   Article
7. Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1.Cancers · 2020
   Article
8. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.Frontiers in immunology · 2020
   Review
9. Mouse tumor susceptibility genes identify drug combinations for multiple myeloma.Journal of cancer metastasis and treatment · 2020
   Article
10. Regulatory mechanisms of B cell responses and the implication in B cell-related diseases.Journal of biomedical science · 2019
    Review
11. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).Blood cancer journal · 2018
    Article
12. Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death.Oncotarget · 2018
    Article
13. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.Clinical epigenetics · 2017
    Review
14. [Advances on immunomodulatory drugs against multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016
    Article
15. Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens.Iranian journal of cancer prevention · 2015
    Review
16. Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model.Oncoimmunology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as